Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Cboe UK GBp

Haleon plc (HLNL.XC)

Compare
392.60
-1.90
(-0.48%)
As of 12:07:39 PM GMT+1. Market Open.
Loading Chart for HLNL.XC
  • Previous Close 394.50
  • Open 395.90
  • Bid 392.40 x --
  • Ask 392.50 x --
  • Day's Range 390.50 - 401.50
  • 52 Week Range 319.30 - 417.70
  • Volume 2,794,262
  • Avg. Volume 4,281,418
  • Market Cap (intraday) 35.477B
  • Beta (5Y Monthly) 0.23
  • PE Ratio (TTM) 2,453.75
  • EPS (TTM) 0.16
  • Earnings Date --
  • Forward Dividend & Yield 0.07 (1.67%)
  • Ex-Dividend Date Apr 24, 2025
  • 1y Target Est --

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Aquafresh, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

www.haleon.com

24,561

Full Time Employees

December 31

Fiscal Year Ends

Recent News: HLNL.XC

View More

Performance Overview: HLNL.XC

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .

YTD Return

HLNL.XC
3.81%
FTSE 100 (^FTSE)
0.35%

1-Year Return

HLNL.XC
21.03%
FTSE 100 (^FTSE)
2.12%

3-Year Return

HLNL.XC
27.27%
FTSE 100 (^FTSE)
7.75%

5-Year Return

HLNL.XC
27.27%
FTSE 100 (^FTSE)
50.40%

Compare To: HLNL.XC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: HLNL.XC

View More

Valuation Measures

Annual
As of 4/3/2025
  • Market Cap

    35.65B

  • Enterprise Value

    43.56B

  • Trailing P/E

    25.13

  • Forward P/E

    20.75

  • PEG Ratio (5yr expected)

    1.84

  • Price/Sales (ttm)

    3.22

  • Price/Book (mrq)

    2.20

  • Enterprise Value/Revenue

    3.88

  • Enterprise Value/EBITDA

    16.57

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    12.84%

  • Return on Assets (ttm)

    4.55%

  • Return on Equity (ttm)

    8.95%

  • Revenue (ttm)

    11.23B

  • Net Income Avi to Common (ttm)

    1.44B

  • Diluted EPS (ttm)

    0.16

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.33B

  • Total Debt/Equity (mrq)

    63.41%

  • Levered Free Cash Flow (ttm)

    2.43B

Research Analysis: HLNL.XC

View More

Company Insights: HLNL.XC

Research Reports: HLNL.XC

View More

People Also Watch

Waiting for permission
Allow microphone access to enable voice search

Try again.